Originally published by our sister publication Specialty Pharmacy Continuum
By SPC Staff
Pfizer is voluntarily withdrawing its sickle cell disease (SCD) medication voxelotor (Oxbryta) from the market due to safety concerns. The FDA advised that healthcare professionals should stop prescribing voxelotor, and patients and caregivers should contact their clinicians about switching to a different treatment option.
Voxelotor received accelerated FDA approval in 2019 for patients aged 12 years and